King's MND Care and Research Centre

King’s College Hospital

King’s MND Care and Research Centre has an equal commitment to providing coordinated care by a multiprofessional team and research into the causes and treatment ALS.

King’s College Hospital

Our center is based at King’s College Hospital in London. The clinic receives referrals from all over the world, and acts as a tertiary referral centre for patients from the South East. In a typical year we will see about 200 new patients and fill 400 follow-up slots making this one of the busiest MND clinics in the world.

Contact
Location
King's College Hospital, Denmark Hill, London, UK

Our Specialists

Ammar Al-Chalabi

Professor of Neurology and Complex Disease Genetics

Professor Ammar Al-Chalabi is head of the Basic and Clinical Neuroscience Department at […]

Ammar Al-Chalabi
Current trials
Recruiting
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Recruiting
Phase iii

ADORE Trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Read more
Recruiting
Phase ii

APL2-ALS-206 Trial

Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more